Novel theranostic agent targets multiple cancer types

A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach. Targeting the neurotensin receptors (NTSRs) that are present in a variety of cancers, CB-2PA-NT has the potential to significantly expand the scope of precision medicine. This research was presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

Leave A Comment

Your email address will not be published. Required fields are marked *